Login to Your Account

Deals And M&A NEWS

Biogen Inc. has moved to buy a midstage neuropsychiatric drug from Pfizer Inc. for $75 million up front, up to $515 million in potential milestones, and tiered royalties in the low to midteens.

DUBLIN – Shares in Evotec AG posted a 13.6 percent gain Thursday on news of another asset transfer deal with Sanofi SA, in which it is getting €60 million up front plus undisclosed long-term funding for taking on a portfolio of 10 preclinical and research-stage anti-infective drug development programs.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: